Frontotemporal dementia (FTD) is a progressive and early-onset neurodegenerative condition, and there are no approved disease-modifying therapies. Despite growing insight into its molecular pathology and the development of biomarkers and genetic stratification tools, drug development for FTD remains limited. Significant challenges include the clinical and pathological heterogeneity of the disease, difficulties in early diagnosis, and limited commercial incentives due to its relative rarity. This editorial highlights the urgent need for coordinated translational research efforts, international collaboration, and robust funding mechanisms to accelerate therapeutic innovation. While the scientific groundwork is promising, overcoming the current therapeutic void requires sustained and strategic global initiatives.
Zabihi, M. (2025). Frontotemporal Dementia and the Therapeutic Void: Bridging the Gap in Drug Development for FTD. Advances in Pharmacology and Therapeutics Journal, 5(2), 103-105. doi: 10.18502/aptj.v5i2.19459
MLA
Zabihi, M. . "Frontotemporal Dementia and the Therapeutic Void: Bridging the Gap in Drug Development for FTD", Advances in Pharmacology and Therapeutics Journal, 5, 2, 2025, 103-105. doi: 10.18502/aptj.v5i2.19459
HARVARD
Zabihi, M. (2025). 'Frontotemporal Dementia and the Therapeutic Void: Bridging the Gap in Drug Development for FTD', Advances in Pharmacology and Therapeutics Journal, 5(2), pp. 103-105. doi: 10.18502/aptj.v5i2.19459
CHICAGO
M. Zabihi, "Frontotemporal Dementia and the Therapeutic Void: Bridging the Gap in Drug Development for FTD," Advances in Pharmacology and Therapeutics Journal, 5 2 (2025): 103-105, doi: 10.18502/aptj.v5i2.19459
VANCOUVER
Zabihi, M. Frontotemporal Dementia and the Therapeutic Void: Bridging the Gap in Drug Development for FTD. Advances in Pharmacology and Therapeutics Journal, 2025; 5(2): 103-105. doi: 10.18502/aptj.v5i2.19459
)